236 related articles for article (PubMed ID: 23077517)
1. Opsonic and protective properties of antibodies raised to conjugate vaccines targeting six Staphylococcus aureus antigens.
Pozzi C; Wilk K; Lee JC; Gening M; Nifantiev N; Pier GB
PLoS One; 2012; 7(10):e46648. PubMed ID: 23077517
[TBL] [Abstract][Full Text] [Related]
2. Natural antibodies in normal human serum inhibit Staphylococcus aureus capsular polysaccharide vaccine efficacy.
Skurnik D; Kropec A; Roux D; Theilacker C; Huebner J; Pier GB
Clin Infect Dis; 2012 Nov; 55(9):1188-97. PubMed ID: 22806596
[TBL] [Abstract][Full Text] [Related]
3. Synthetic {beta}-(1->6)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogens.
Gening ML; Maira-Litrán T; Kropec A; Skurnik D; Grout M; Tsvetkov YE; Nifantiev NE; Pier GB
Infect Immun; 2010 Feb; 78(2):764-72. PubMed ID: 19948836
[TBL] [Abstract][Full Text] [Related]
4. Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal Poly-N-acetyl-beta-(1-6)-glucosamine.
Maira-Litrán T; Kropec A; Goldmann DA; Pier GB
Infect Immun; 2005 Oct; 73(10):6752-62. PubMed ID: 16177353
[TBL] [Abstract][Full Text] [Related]
5. Animal and human antibodies to distinct Staphylococcus aureus antigens mutually neutralize opsonic killing and protection in mice.
Skurnik D; Merighi M; Grout M; Gadjeva M; Maira-Litran T; Ericsson M; Goldmann DA; Huang SS; Datta R; Lee JC; Pier GB
J Clin Invest; 2010 Sep; 120(9):3220-33. PubMed ID: 20739753
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of a conjugate vaccine composed of Staphylococcus aureus poly-N-acetyl-glucosamine and clumping factor A.
Maira-Litrán T; Bentancor LV; Bozkurt-Guzel C; O'Malley JM; Cywes-Bentley C; Pier GB
PLoS One; 2012; 7(9):e43813. PubMed ID: 22970144
[TBL] [Abstract][Full Text] [Related]
7. Antibodies to Staphylococcus aureus serotype 8 capsular polysaccharide react with and protect against serotype 5 and 8 isolates.
Park S; Gerber S; Lee JC
Infect Immun; 2014 Dec; 82(12):5049-55. PubMed ID: 25245803
[TBL] [Abstract][Full Text] [Related]
8. Antibodies to Staphylococcus aureus capsular polysaccharides 5 and 8 perform similarly in vitro but are functionally distinct in vivo.
Liu B; Park S; Thompson CD; Li X; Lee JC
Virulence; 2017 Aug; 8(6):859-874. PubMed ID: 27936346
[TBL] [Abstract][Full Text] [Related]
9. Immunization with outer membrane vesicles displaying conserved surface polysaccharide antigen elicits broadly antimicrobial antibodies.
Stevenson TC; Cywes-Bentley C; Moeller TD; Weyant KB; Putnam D; Chang YF; Jones BD; Pier GB; DeLisa MP
Proc Natl Acad Sci U S A; 2018 Apr; 115(14):E3106-E3115. PubMed ID: 29555731
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis for preferential protective efficacy of antibodies directed to the poorly acetylated form of staphylococcal poly-N-acetyl-beta-(1-6)-glucosamine.
Cerca N; Jefferson KK; Maira-Litrán T; Pier DB; Kelly-Quintos C; Goldmann DA; Azeredo J; Pier GB
Infect Immun; 2007 Jul; 75(7):3406-13. PubMed ID: 17470540
[TBL] [Abstract][Full Text] [Related]
11. Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis.
Lattar SM; Noto Llana M; Denoël P; Germain S; Buzzola FR; Lee JC; Sordelli DO
Infect Immun; 2014 Jan; 82(1):83-91. PubMed ID: 24126523
[TBL] [Abstract][Full Text] [Related]
12. Antibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogens.
Cywes-Bentley C; Skurnik D; Zaidi T; Roux D; Deoliveira RB; Garrett WS; Lu X; O'Malley J; Kinzel K; Zaidi T; Rey A; Perrin C; Fichorova RN; Kayatani AK; Maira-Litràn T; Gening ML; Tsvetkov YE; Nifantiev NE; Bakaletz LO; Pelton SI; Golenbock DT; Pier GB
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):E2209-18. PubMed ID: 23716675
[TBL] [Abstract][Full Text] [Related]
13. The role of epitope specificity in the human opsonic antibody response to the staphylococcal surface polysaccharide poly N-acetyl glucosamine.
Kelly-Quintos C; Kropec A; Briggs S; Ordonez CL; Goldmann DA; Pier GB
J Infect Dis; 2005 Dec; 192(11):2012-9. PubMed ID: 16267775
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-N-acetylglucosamine.
Kelly-Quintos C; Cavacini LA; Posner MR; Goldmann D; Pier GB
Infect Immun; 2006 May; 74(5):2742-50. PubMed ID: 16622211
[TBL] [Abstract][Full Text] [Related]
15. A Poly-N-acetylglucosamine-Shiga toxin broad-spectrum conjugate vaccine for Shiga toxin-producing Escherichia coli.
Lu X; Skurnik D; Pozzi C; Roux D; Cywes-Bentley C; Ritchie JM; Munera D; Gening ML; Tsvetkov YE; Nifantiev NE; Waldor MK; Pier GB
mBio; 2014 Mar; 5(2):e00974-14. PubMed ID: 24667709
[TBL] [Abstract][Full Text] [Related]
16. SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies.
Begier E; Seiden DJ; Patton M; Zito E; Severs J; Cooper D; Eiden J; Gruber WC; Jansen KU; Anderson AS; Gurtman A
Vaccine; 2017 Feb; 35(8):1132-1139. PubMed ID: 28143674
[TBL] [Abstract][Full Text] [Related]
17. Protection against Escherichia coli infection by antibody to the Staphylococcus aureus poly-N-acetylglucosamine surface polysaccharide.
Cerca N; Maira-Litrán T; Jefferson KK; Grout M; Goldmann DA; Pier GB
Proc Natl Acad Sci U S A; 2007 May; 104(18):7528-33. PubMed ID: 17446272
[TBL] [Abstract][Full Text] [Related]
18. Antibody to Poly-N-acetyl glucosamine provides protection against intracellular pathogens: Mechanism of action and validation in horse foals challenged with Rhodococcus equi.
Cywes-Bentley C; Rocha JN; Bordin AI; Vinacur M; Rehman S; Zaidi TS; Meyer M; Anthony S; Lambert M; Vlock DR; Giguère S; Cohen ND; Pier GB
PLoS Pathog; 2018 Jul; 14(7):e1007160. PubMed ID: 30024986
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial.
Creech CB; Frenck RW; Sheldon EA; Seiden DJ; Kankam MK; Zito ET; Girgenti D; Severs JM; Immermann FW; McNeil LK; Cooper D; Jansen KU; Gruber W; Eiden J; Anderson AS; Baber J
Vaccine; 2017 Jan; 35(2):385-394. PubMed ID: 27866765
[TBL] [Abstract][Full Text] [Related]
20. Biological characteristics and conjugated antigens of ClfA A-FnBPA and CP5 in
Li T; Huang M; Song Z; Zhang H; Chen C
Can J Vet Res; 2018 Jan; 82(1):48-54. PubMed ID: 29382968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
